
Oncology NEWS International
- Oncology NEWS International Vol 5 No 5
- Volume 5
- Issue 5
DaunoXome Cleared For Kaposi's Sarcoma
BOULDER, Colorado--NeXstar Pharmaceutical's DaunoXome (dauno-rubicin citrate liposome injection) has received FDA approval for use as primary therapy for advanced HIV-associated Kaposi's sarcoma (KS).
BOULDER, Colorado--NeXstar Pharmaceutical's DaunoXome (dauno-rubicincitrate liposome injection) has received FDA approval for useas primary therapy for advanced HIV-associated Kaposi's sarcoma(KS).
In the company-sponsored phase III trial, conducted at 13 US andCanadian centers and involving 227 patients with advanced HIV-associatedKS, Dauno-Xome was found to have efficacy comparable to the three-drugregimen of Adria-mycin, bleomycin, and vincristine (ABV).
Average survival was 342 days for patients on DaunoXome vs 291days for those on ABV. Side effects such as neu-ropathy and alopeciawere reduced significantly with use of DaunoXome.
Articles in this issue
almost 30 years ago
No Need to Delay Mammography After FNA, Study Showsalmost 30 years ago
Pediatric Cancer Guidelines Are a National Effortalmost 30 years ago
EPA Proposes Changes in Determining Cancer Risk of Chemicals, Pollutantsalmost 30 years ago
ATL's HDI Digital Ultrasound Is Approved for Breast Indicationalmost 30 years ago
NIH Study Suggests That 200 mg Is The Optimal Daily Dose of Vitamin Calmost 30 years ago
Natural History of HIV Supports the Use Of Early Interventionsalmost 30 years ago
Aids Vaccine Trial Fails to Show Clinical Benefitalmost 30 years ago
Rep. Porter Honored For Work on BudgetNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.




































